General Information:

Id: 6,515 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Rattus norvegicus
Reference: Zhang CX et al.(2011) Metformin attenuates ventricular hypertrophy by activating the AMP-activated protein kinase-endothelial nitric oxide synthase pathway in rats Clin. Exp. Pharmacol. Physiol. 38: 55-62 [PMID: 21083698]

Interaction Information:

Comment In cardiomyocytes, metformin inhibited AngII-induced protein synthesis, an effect that was suppressed by the AMPK inhibitor compound C or the eNOS inhibitor L-NAME. The improvement in cardiac structure and function following metformin treatment was associated with enhanced phosphorylation of AMPK and eNOS and increased NO production. The findings indicate that long-term treatment with metformin could attenuate ventricular hypertrophy induced by pressure overload via activation of AMPK and a downstream signalling pathway involving eNOS-NO.
Formal Description
Interaction-ID: 61951

drug/chemical compound


decreases_activity of


Angiotensin II

in cardiac muscle
Drugbank entries Show/Hide entries for Metformin